Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.5.4.4 (adenosine deaminase)
 5,136 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Tamoxifen is a synthetic non steroidal anti-estrogen used to treat patients with breast cancer and healthy subjects with high risk of breast cancer. It was aimed to study the short term effects of tamoxifen on the plasma total antioxidant capacity (TAC), nitric oxide (NO) and the adenosine deaminase activity (ADA) in healthy rabbits. Sixteen healthy New Zealand rabbits were allocated to 2 groups including controls and tamoxifen treated animals. Controls received a single application of 0.9% saline via oral route while the treated rabbits received orally tamoxifen (dissolved in 0.9% saline, at a dose of 5 mg/kg). Blood samples were collected at 6 and 24 hours following the treatments. Plasma TAC and ADA were not affected by Tamoxifen treatment. However, NO level in tamoxifen treated group was increased at 24 hours following tamoxifen treatment as compared to controls. In conclusion, acute tamoxifen treatment may not affect the antioxidant status and cellular immunity, as evidenced by unaltered TAC and ADA. However, NO level was increased as early as 24 hours following tamoxifen treatment.
 ...
PMID:Acute tamoxifen treatment increases nitric oxide level but not total antioxidant capacity and adenosine deaminase activity in the plasma of rabbits. 1969 40

Recent findings suggest that inhibition of AMP-deaminase (AMPD) could be effective therapeutic strategy in heart disease associated with cardiac ischemia. To establish experimental model to study protective mechanisms of AMPD inhibition we developed conditional, cardiac specific knock-outs in Cre recombinase system. AMPD3 floxed mice were crossed with Mer-Cre-Mer mice. Tamoxifen was injected to induce Cre recombinase. After two weeks, hearts, skeletal muscle, liver, kidney, and blood were collected and activities of AMPD and related enzymes were analyzed using HPLC-based procedure. We demonstrate loss of more than 90% of cardiac AMPD activity in the heart of AMPD3-/-mice while other enzymes of nucleotide metabolism such as adenosine deaminase, purine nucleoside phosphorylase were not affected. Surprisingly, activity of AMPD was also reduced in the erythrocytes and in the kidney by 20%-30%. No change of AMPD activity was observed in the skeletal muscle and the liver.
 ...
PMID:Effect of AMP-deaminase 3 knock-out in mice on enzyme activity in heart and other organs. 2494 Jun 86